Kurt Rasmussen

Company: Delix Therapeutics

Job title: Chief Scientific Officer

Seminars:

Examining the Preclinical Pharmacology of Novel Neuroplastogens 11:30 am

Presenting effects on in vivo structural and functional neuroplasticity Activity in animal models of antidepressant activity Opportunities across neuropsychiatric indicationsRead more

day: Track 1 AM Day 2

Workshop A: From Underlying Mechanisms to Clinical Efficacy: Deepening Understanding of the Psychedelic Mode of Action & Hallucinogenic Effects 9:00 am

Investment in psychedelic R&D is growing, with notable approvals on the horizon, however, the underlying mechanisms and receptor interactions driving clinical efficacy remain poorly understood. Join this workshop to uncover new knowledge of underlying psychedelic mechanisms, decipher the role of 5HT2A, debate the necessity hallucinogenic effects, and examine recent clinical efficacy data. Address critical questions,…Read more

day: Pre Conf Day - A